Cold Genesys is a biopharmaceutical company that’s developing an immunotherapy treatment to treat bladder cancer. Founded in 2010 by Paul DeRidder, Cold Genesys has raised $22M in Series C funding led by ORI Healthcare Fund, along with participation from Perseverance Capital Management. It has now raised a total of $45.6M across three rounds.
Page 2 of 3
